EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 356 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce MOST POPULAR The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not... March 1, 2021 Smoking addiction killed my grandfather – now it’s up to the... December 29, 2022 What to Know About Returning to Work After Cancer Treatment: An... February 15, 2024 EMA Recommends Extension of Indications for Inotuzumab Ozogamicin April 29, 2026 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide How Can Hormone Replacement Therapy for Menopause Impact My Cancer Risk? Help seeking: Why isn’t it as simple as it might sound? Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With...
